Zacks Investment Research
14 Oct 2026, 18:41 UTC · 1h ago
Roche Expands Obesity Pipeline With Rona's RNAi Candidate
Impact · against what's priced in
Roche is diversifying its obesity strategy by adding a non-incretin RNAi candidate to its pipeline, reducing reliance on GLP-1 pathways. While mid-stage success for enicepatide is likely already expected, the ALK7 licensing agreement provides a new, differentiated path toward treating visceral fat.
- RHHBY+0.40
No priced-in read yet
- In context
The exclusive license for an ALK7 RNAi candidate creates a differentiated obesity play that avoids the crowded incretin space, adding potential value of up to $1.16 billion.
Read from the article alone
Top 1 mover · tap to explore
